Research
Hormonal
Adiponectin improves metabolic health by activating ceramidase, which degrades ceramide and promotes the production of sphingosine-1-phosphate (S1P), thereby opposing ceramide's inhibitory effects on insulin signaling.
Adiponectin, a hormone that improves insulin sensitivity, works by breaking down toxic ceramides. Since adiponectin levels are often low in obesity, maintaining a healthy weight and exercising may be the most effective way to support this protective hormonal pathway.
ModerateSupportsMEDIUM confidence
adiponectin receptors activate cellular ceramidase activity, resulting in the degradation of ceramide to form sphingosine... increases in sphingosine by the ceramidase activity of adiponectin receptors lead to elevations in a downstream product, sphingosine 1-phosphate (S1P), which opposes ceramide action.
Why this rating
Based on cell culture and rodent models; human data is correlational.
Source
Ceramides as modulators of cellular and whole-body metabolism
Benjamin T. Bikman et al. · Journal of Clinical Investigation · 2011
DOI 10.1172/jci57144
narrative_reviewCited 411×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Inhibition of de novo ceramide synthesis (via SPT inhibitors like myriocin or genetic knockdown) reverses insulin resistance and improves glucose tolerance in rodent models of obesity and high-fat feeding.Moderate
- Saturated fatty acids induce insulin resistance by activating TLR4, which drives the transcriptional upregulation of enzymes for de novo ceramide synthesis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →